sales@marketresearchvision.com

30 mins free consultation for each report        Upto 50% Discounts for Highest selling reports


COVID-19 Impact on Global Inactivated Vaccine, Market Insights and Forecast to 2026

COVID-19 Impact on Global Inactivated Vaccine, Market Insights and Forecast to 2026

Category : Pharmaceuticals and Healthcare QY Research Pages :117
Published Date : 2020-09-16

 

Covid-19

COVID-19

Understand the influence of COVID-19 on the Inactivated Vaccine Market with our analysts monitoring the situation across the globe.
Inactivated Vaccine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Inactivated Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026. Segment by Type, the Inactivated Vaccine market is segmented into Children Adult Segment by Application, the Inactivated Vaccine market is segmented into Hospital Medical Center Regional and Country-level Analysis The Inactivated Vaccine market is analysed and market size information is provided by regions (countries). The key regions covered in the Inactivated Vaccine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026. Competitive Landscape and Inactivated Vaccine Market Share Analysis Inactivated Vaccine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Inactivated Vaccine business, the date to enter into the Inactivated Vaccine market, Inactivated Vaccine product introduction, recent developments, etc. The major vendors covered: Astellas Pharma (Japan) CSL Limited (Australia) Emergent BioSolutions (U.S.) GlaxoSmithKline (U.K.) Johnson & Johnson (U.S.) MedImmune (U.S.) Merck & Co (U.S.) Pfizer (U.S.) Sanofi Pasteur (France) Serum Institute of India Pvt (India)
1 Study Coverage 1.1 Inactivated Vaccine Product Introduction 1.2 Market Segments 1.3 Key Inactivated Vaccine Manufacturers Covered: Ranking by Revenue 1.4 Market by Type 1.4.1 Global Inactivated Vaccine Market Size Growth Rate by Type 1.4.2 Children 1.4.3 Adult 1.5 Market by Application 1.5.1 Global Inactivated Vaccine Market Size Growth Rate by Application 1.5.2 Hospital 1.5.3 Medical Center 1.6 Coronavirus Disease 2019 (Covid-19): Inactivated Vaccine Industry Impact 1.6.1 How the Covid-19 is Affecting the Inactivated Vaccine Industry 1.6.1.1 Inactivated Vaccine Business Impact Assessment - Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Inactivated Vaccine Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Inactivated Vaccine Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global Inactivated Vaccine Market Size Estimates and Forecasts 2.1.1 Global Inactivated Vaccine Revenue 2015-2026 2.1.2 Global Inactivated Vaccine Sales 2015-2026 2.2 Inactivated Vaccine Market Size by Region: 2020 Versus 2026 2.2.1 Global Inactivated Vaccine Retrospective Market Scenario in Sales by Region: 2015-2020 2.2.2 Global Inactivated Vaccine Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Inactivated Vaccine Competitor Landscape by Players 3.1 Inactivated Vaccine Sales by Manufacturers 3.1.1 Inactivated Vaccine Sales by Manufacturers (2015-2020) 3.1.2 Inactivated Vaccine Sales Market Share by Manufacturers (2015-2020) 3.2 Inactivated Vaccine Revenue by Manufacturers 3.2.1 Inactivated Vaccine Revenue by Manufacturers (2015-2020) 3.2.2 Inactivated Vaccine Revenue Share by Manufacturers (2015-2020) 3.2.3 Global Inactivated Vaccine Market Concentration Ratio (CR5 and HHI) (2015-2020) 3.2.4 Global Top 10 and Top 5 Companies by Inactivated Vaccine Revenue in 2019 3.2.5 Global Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Inactivated Vaccine Price by Manufacturers 3.4 Inactivated Vaccine Manufacturing Base Distribution, Product Types 3.4.1 Inactivated Vaccine Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Inactivated Vaccine Product Type 3.4.3 Date of International Manufacturers Enter into Inactivated Vaccine Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Inactivated Vaccine Market Size by Type (2015-2020) 4.1.1 Global Inactivated Vaccine Sales by Type (2015-2020) 4.1.2 Global Inactivated Vaccine Revenue by Type (2015-2020) 4.1.3 Inactivated Vaccine Average Selling Price (ASP) by Type (2015-2026) 4.2 Global Inactivated Vaccine Market Size Forecast by Type (2021-2026) 4.2.1 Global Inactivated Vaccine Sales Forecast by Type (2021-2026) 4.2.2 Global Inactivated Vaccine Revenue Forecast by Type (2021-2026) 4.2.3 Inactivated Vaccine Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Inactivated Vaccine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026) 5.1 Global Inactivated Vaccine Market Size by Application (2015-2020) 5.1.1 Global Inactivated Vaccine Sales by Application (2015-2020) 5.1.2 Global Inactivated Vaccine Revenue by Application (2015-2020) 5.1.3 Inactivated Vaccine Price by Application (2015-2020) 5.2 Inactivated Vaccine Market Size Forecast by Application (2021-2026) 5.2.1 Global Inactivated Vaccine Sales Forecast by Application (2021-2026) 5.2.2 Global Inactivated Vaccine Revenue Forecast by Application (2021-2026) 5.2.3 Global Inactivated Vaccine Price Forecast by Application (2021-2026) 6 North America 6.1 North America Inactivated Vaccine by Country 6.1.1 North America Inactivated Vaccine Sales by Country 6.1.2 North America Inactivated Vaccine Revenue by Country 6.1.3 U.S. 6.1.4 Canada 6.2 North America Inactivated Vaccine Market Facts & Figures by Type 6.3 North America Inactivated Vaccine Market Facts & Figures by Application 7 Europe 7.1 Europe Inactivated Vaccine by Country 7.1.1 Europe Inactivated Vaccine Sales by Country 7.1.2 Europe Inactivated Vaccine Revenue by Country 7.1.3 Germany 7.1.4 France 7.1.5 U.K. 7.1.6 Italy 7.1.7 Russia 7.2 Europe Inactivated Vaccine Market Facts & Figures by Type 7.3 Europe Inactivated Vaccine Market Facts & Figures by Application 8 Asia Pacific 8.1 Asia Pacific Inactivated Vaccine by Region 8.1.1 Asia Pacific Inactivated Vaccine Sales by Region 8.1.2 Asia Pacific Inactivated Vaccine Revenue by Region 8.1.3 China 8.1.4 Japan 8.1.5 South Korea 8.1.6 India 8.1.7 Australia 8.1.8 Taiwan 8.1.9 Indonesia 8.1.10 Thailand 8.1.11 Malaysia 8.1.12 Philippines 8.1.13 Vietnam 8.2 Asia Pacific Inactivated Vaccine Market Facts & Figures by Type 8.3 Asia Pacific Inactivated Vaccine Market Facts & Figures by Application 9 Latin America 9.1 Latin America Inactivated Vaccine by Country 9.1.1 Latin America Inactivated Vaccine Sales by Country 9.1.2 Latin America Inactivated Vaccine Revenue by Country 9.1.3 Mexico 9.1.4 Brazil 9.1.5 Argentina 9.2 Central & South America Inactivated Vaccine Market Facts & Figures by Type 9.3 Central & South America Inactivated Vaccine Market Facts & Figures by Application 10 Middle East and Africa 10.1 Middle East and Africa Inactivated Vaccine by Country 10.1.1 Middle East and Africa Inactivated Vaccine Sales by Country 10.1.2 Middle East and Africa Inactivated Vaccine Revenue by Country 10.1.3 Turkey 10.1.4 Saudi Arabia 10.1.5 U.A.E 10.2 Middle East and Africa Inactivated Vaccine Market Facts & Figures by Type 10.3 Middle East and Africa Inactivated Vaccine Market Facts & Figures by Application 11 Company Profiles 11.1 Astellas Pharma (Japan) 11.1.1 Astellas Pharma (Japan) Corporation Information 11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue 11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Astellas Pharma (Japan) Inactivated Vaccine Products Offered 11.1.5 Astellas Pharma (Japan) Recent Development 11.2 CSL Limited (Australia) 11.2.1 CSL Limited (Australia) Corporation Information 11.2.2 CSL Limited (Australia) Description, Business Overview and Total Revenue 11.2.3 CSL Limited (Australia) Sales, Revenue and Gross Margin (2015-2020) 11.2.4 CSL Limited (Australia) Inactivated Vaccine Products Offered 11.2.5 CSL Limited (Australia) Recent Development 11.3 Emergent BioSolutions (U.S.) 11.3.1 Emergent BioSolutions (U.S.) Corporation Information 11.3.2 Emergent BioSolutions (U.S.) Description, Business Overview and Total Revenue 11.3.3 Emergent BioSolutions (U.S.) Sales, Revenue and Gross Margin (2015-2020) 11.3.4 Emergent BioSolutions (U.S.) Inactivated Vaccine Products Offered 11.3.5 Emergent BioSolutions (U.S.) Recent Development 11.4 GlaxoSmithKline (U.K.) 11.4.1 GlaxoSmithKline (U.K.) Corporation Information 11.4.2 GlaxoSmithKline (U.K.) Description, Business Overview and Total Revenue 11.4.3 GlaxoSmithKline (U.K.) Sales, Revenue and Gross Margin (2015-2020) 11.4.4 GlaxoSmithKline (U.K.) Inactivated Vaccine Products Offered 11.4.5 GlaxoSmithKline (U.K.) Recent Development 11.5 Johnson & Johnson (U.S.) 11.5.1 Johnson & Johnson (U.S.) Corporation Information 11.5.2 Johnson & Johnson (U.S.) Description, Business Overview and Total Revenue 11.5.3 Johnson & Johnson (U.S.) Sales, Revenue and Gross Margin (2015-2020) 11.5.4 Johnson & Johnson (U.S.) Inactivated Vaccine Products Offered 11.5.5 Johnson & Johnson (U.S.) Recent Development 11.6 MedImmune (U.S.) 11.6.1 MedImmune (U.S.) Corporation Information 11.6.2 MedImmune (U.S.) Description, Business Overview and Total Revenue 11.6.3 MedImmune (U.S.) Sales, Revenue and Gross Margin (2015-2020) 11.6.4 MedImmune (U.S.) Inactivated Vaccine Products Offered 11.6.5 MedImmune (U.S.) Recent Development 11.7 Merck & Co (U.S.) 11.7.1 Merck & Co (U.S.) Corporation Information 11.7.2 Merck & Co (U.S.) Description, Business Overview and Total Revenue 11.7.3 Merck & Co (U.S.) Sales, Revenue and Gross Margin (2015-2020) 11.7.4 Merck & Co (U.S.) Inactivated Vaccine Products Offered 11.7.5 Merck & Co (U.S.) Recent Development 11.8 Pfizer (U.S.) 11.8.1 Pfizer (U.S.) Corporation Information 11.8.2 Pfizer (U.S.) Description, Business Overview and Total Revenue 11.8.3 Pfizer (U.S.) Sales, Revenue and Gross Margin (2015-2020) 11.8.4 Pfizer (U.S.) Inactivated Vaccine Products Offered 11.8.5 Pfizer (U.S.) Recent Development 11.9 Sanofi Pasteur (France) 11.9.1 Sanofi Pasteur (France) Corporation Information 11.9.2 Sanofi Pasteur (France) Description, Business Overview and Total Revenue 11.9.3 Sanofi Pasteur (France) Sales, Revenue and Gross Margin (2015-2020) 11.9.4 Sanofi Pasteur (France) Inactivated Vaccine Products Offered 11.9.5 Sanofi Pasteur (France) Recent Development 11.10 Serum Institute of India Pvt (India) 11.10.1 Serum Institute of India Pvt (India) Corporation Information 11.10.2 Serum Institute of India Pvt (India) Description, Business Overview and Total Revenue 11.10.3 Serum Institute of India Pvt (India) Sales, Revenue and Gross Margin (2015-2020) 11.10.4 Serum Institute of India Pvt (India) Inactivated Vaccine Products Offered 11.10.5 Serum Institute of India Pvt (India) Recent Development 11.1 Astellas Pharma (Japan) 11.1.1 Astellas Pharma (Japan) Corporation Information 11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue 11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Astellas Pharma (Japan) Inactivated Vaccine Products Offered 11.1.5 Astellas Pharma (Japan) Recent Development 12 Future Forecast by Regions (Countries) (2021-2026) 12.1 Inactivated Vaccine Market Estimates and Projections by Region 12.1.1 Global Inactivated Vaccine Sales Forecast by Regions 2021-2026 12.1.2 Global Inactivated Vaccine Revenue Forecast by Regions 2021-2026 12.2 North America Inactivated Vaccine Market Size Forecast (2021-2026) 12.2.1 North America: Inactivated Vaccine Sales Forecast (2021-2026) 12.2.2 North America: Inactivated Vaccine Revenue Forecast (2021-2026) 12.2.3 North America: Inactivated Vaccine Market Size Forecast by Country (2021-2026) 12.3 Europe Inactivated Vaccine Market Size Forecast (2021-2026) 12.3.1 Europe: Inactivated Vaccine Sales Forecast (2021-2026) 12.3.2 Europe: Inactivated Vaccine Revenue Forecast (2021-2026) 12.3.3 Europe: Inactivated Vaccine Market Size Forecast by Country (2021-2026) 12.4 Asia Pacific Inactivated Vaccine Market Size Forecast (2021-2026) 12.4.1 Asia Pacific: Inactivated Vaccine Sales Forecast (2021-2026) 12.4.2 Asia Pacific: Inactivated Vaccine Revenue Forecast (2021-2026) 12.4.3 Asia Pacific: Inactivated Vaccine Market Size Forecast by Region (2021-2026) 12.5 Latin America Inactivated Vaccine Market Size Forecast (2021-2026) 12.5.1 Latin America: Inactivated Vaccine Sales Forecast (2021-2026) 12.5.2 Latin America: Inactivated Vaccine Revenue Forecast (2021-2026) 12.5.3 Latin America: Inactivated Vaccine Market Size Forecast by Country (2021-2026) 12.6 Middle East and Africa Inactivated Vaccine Market Size Forecast (2021-2026) 12.6.1 Middle East and Africa: Inactivated Vaccine Sales Forecast (2021-2026) 12.6.2 Middle East and Africa: Inactivated Vaccine Revenue Forecast (2021-2026) 12.6.3 Middle East and Africa: Inactivated Vaccine Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Market Opportunities and Drivers 13.2 Market Challenges 13.3 Market Risks/Restraints 13.4 Porter’s Five Forces Analysis 13.5 Primary Interviews with Key Inactivated Vaccine Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Inactivated Vaccine Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details

Get Free Sample

List of Tables Table 1. Inactivated Vaccine Market Segments Table 2. Ranking of Global Top Inactivated Vaccine Manufacturers by Revenue (US$ Million) in 2019 Table 3. Global Inactivated Vaccine Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million) Table 4. Major Manufacturers of Children Table 5. Major Manufacturers of Adult Table 6. COVID-19 Impact Global Market: (Four Inactivated Vaccine Market Size Forecast Scenarios) Table 7. Opportunities and Trends for Inactivated Vaccine Players in the COVID-19 Landscape Table 8. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis Table 9. Key Regions/Countries Measures against Covid-19 Impact Table 10. Proposal for Inactivated Vaccine Players to Combat Covid-19 Impact Table 11. Global Inactivated Vaccine Market Size Growth Rate by Application 2020-2026 (K MT) Table 12. Global Inactivated Vaccine Market Size by Region (K MT) & (US$ Million): 2020 VS 2026 Table 13. Global Inactivated Vaccine Sales by Regions 2015-2020 (K MT) Table 14. Global Inactivated Vaccine Sales Market Share by Regions (2015-2020) Table 15. Global Inactivated Vaccine Revenue by Regions 2015-2020 (US$ Million) Table 16. Global Inactivated Vaccine Sales by Manufacturers (2015-2020) (K MT) Table 17. Global Inactivated Vaccine Sales Share by Manufacturers (2015-2020) Table 18. Global Inactivated Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020) Table 19. Global Inactivated Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Inactivated Vaccine as of 2019) Table 20. Inactivated Vaccine Revenue by Manufacturers (2015-2020) (US$ Million) Table 21. Inactivated Vaccine Revenue Share by Manufacturers (2015-2020) Table 22. Key Manufacturers Inactivated Vaccine Price (2015-2020) (USD/MT) Table 23. Inactivated Vaccine Manufacturers Manufacturing Base Distribution and Headquarters Table 24. Manufacturers Inactivated Vaccine Product Type Table 25. Date of International Manufacturers Enter into Inactivated Vaccine Market Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans Table 27. Global Inactivated Vaccine Sales by Type (2015-2020) (K MT) Table 28. Global Inactivated Vaccine Sales Share by Type (2015-2020) Table 29. Global Inactivated Vaccine Revenue by Type (2015-2020) (US$ Million) Table 30. Global Inactivated Vaccine Revenue Share by Type (2015-2020) Table 31. Inactivated Vaccine Average Selling Price (ASP) by Type 2015-2020 (USD/MT) Table 32. Global Inactivated Vaccine Sales by Application (2015-2020) (K MT) Table 33. Global Inactivated Vaccine Sales Share by Application (2015-2020) Table 34. North America Inactivated Vaccine Sales by Country (2015-2020) (K MT) Table 35. North America Inactivated Vaccine Sales Market Share by Country (2015-2020) Table 36. North America Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million) Table 37. North America Inactivated Vaccine Revenue Market Share by Country (2015-2020) Table 38. North America Inactivated Vaccine Sales by Type (2015-2020) (K MT) Table 39. North America Inactivated Vaccine Sales Market Share by Type (2015-2020) Table 40. North America Inactivated Vaccine Sales by Application (2015-2020) (K MT) Table 41. North America Inactivated Vaccine Sales Market Share by Application (2015-2020) Table 42. Europe Inactivated Vaccine Sales by Country (2015-2020) (K MT) Table 43. Europe Inactivated Vaccine Sales Market Share by Country (2015-2020) Table 44. Europe Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million) Table 45. Europe Inactivated Vaccine Revenue Market Share by Country (2015-2020) Table 46. Europe Inactivated Vaccine Sales by Type (2015-2020) (K MT) Table 47. Europe Inactivated Vaccine Sales Market Share by Type (2015-2020) Table 48. Europe Inactivated Vaccine Sales by Application (2015-2020) (K MT) Table 49. Europe Inactivated Vaccine Sales Market Share by Application (2015-2020) Table 50. Asia Pacific Inactivated Vaccine Sales by Region (2015-2020) (K MT) Table 51. Asia Pacific Inactivated Vaccine Sales Market Share by Region (2015-2020) Table 52. Asia Pacific Inactivated Vaccine Revenue by Region (2015-2020) (US$ Million) Table 53. Asia Pacific Inactivated Vaccine Revenue Market Share by Region (2015-2020) Table 54. Asia Pacific Inactivated Vaccine Sales by Type (2015-2020) (K MT) Table 55. Asia Pacific Inactivated Vaccine Sales Market Share by Type (2015-2020) Table 56. Asia Pacific Inactivated Vaccine Sales by Application (2015-2020) (K MT) Table 57. Asia Pacific Inactivated Vaccine Sales Market Share by Application (2015-2020) Table 58. Latin America Inactivated Vaccine Sales by Country (2015-2020) (K MT) Table 59. Latin America Inactivated Vaccine Sales Market Share by Country (2015-2020) Table 60. Latin Americaa Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million) Table 61. Latin America Inactivated Vaccine Revenue Market Share by Country (2015-2020) Table 62. Latin America Inactivated Vaccine Sales by Type (2015-2020) (K MT) Table 63. Latin America Inactivated Vaccine Sales Market Share by Type (2015-2020) Table 64. Latin America Inactivated Vaccine Sales by Application (2015-2020) (K MT) Table 65. Latin America Inactivated Vaccine Sales Market Share by Application (2015-2020) Table 66. Middle East and Africa Inactivated Vaccine Sales by Country (2015-2020) (K MT) Table 67. Middle East and Africa Inactivated Vaccine Sales Market Share by Country (2015-2020) Table 68. Middle East and Africa Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million) Table 69. Middle East and Africa Inactivated Vaccine Revenue Market Share by Country (2015-2020) Table 70. Middle East and Africa Inactivated Vaccine Sales by Type (2015-2020) (K MT) Table 71. Middle East and Africa Inactivated Vaccine Sales Market Share by Type (2015-2020) Table 72. Middle East and Africa Inactivated Vaccine Sales by Application (2015-2020) (K MT) Table 73. Middle East and Africa Inactivated Vaccine Sales Market Share by Application (2015-2020) Table 74. Astellas Pharma (Japan) Corporation Information Table 75. Astellas Pharma (Japan) Description and Major Businesses Table 76. Astellas Pharma (Japan) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 77. Astellas Pharma (Japan) Product Table 78. Astellas Pharma (Japan) Recent Development Table 79. CSL Limited (Australia) Corporation Information Table 80. CSL Limited (Australia) Description and Major Businesses Table 81. CSL Limited (Australia) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 82. CSL Limited (Australia) Product Table 83. CSL Limited (Australia) Recent Development Table 84. Emergent BioSolutions (U.S.) Corporation Information Table 85. Emergent BioSolutions (U.S.) Description and Major Businesses Table 86. Emergent BioSolutions (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 87. Emergent BioSolutions (U.S.) Product Table 88. Emergent BioSolutions (U.S.) Recent Development Table 89. GlaxoSmithKline (U.K.) Corporation Information Table 90. GlaxoSmithKline (U.K.) Description and Major Businesses Table 91. GlaxoSmithKline (U.K.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 92. GlaxoSmithKline (U.K.) Product Table 93. GlaxoSmithKline (U.K.) Recent Development Table 94. Johnson & Johnson (U.S.) Corporation Information Table 95. Johnson & Johnson (U.S.) Description and Major Businesses Table 96. Johnson & Johnson (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 97. Johnson & Johnson (U.S.) Product Table 98. Johnson & Johnson (U.S.) Recent Development Table 99. MedImmune (U.S.) Corporation Information Table 100. MedImmune (U.S.) Description and Major Businesses Table 101. MedImmune (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 102. MedImmune (U.S.) Product Table 103. MedImmune (U.S.) Recent Development Table 104. Merck & Co (U.S.) Corporation Information Table 105. Merck & Co (U.S.) Description and Major Businesses Table 106. Merck & Co (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 107. Merck & Co (U.S.) Product Table 108. Merck & Co (U.S.) Recent Development Table 109. Pfizer (U.S.) Corporation Information Table 110. Pfizer (U.S.) Description and Major Businesses Table 111. Pfizer (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 112. Pfizer (U.S.) Product Table 113. Pfizer (U.S.) Recent Development Table 114. Sanofi Pasteur (France) Corporation Information Table 115. Sanofi Pasteur (France) Description and Major Businesses Table 116. Sanofi Pasteur (France) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 117. Sanofi Pasteur (France) Product Table 118. Sanofi Pasteur (France) Recent Development Table 119. Serum Institute of India Pvt (India) Corporation Information Table 120. Serum Institute of India Pvt (India) Description and Major Businesses Table 121. Serum Institute of India Pvt (India) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020) Table 122. Serum Institute of India Pvt (India) Product Table 123. Serum Institute of India Pvt (India) Recent Development Table 124. Global Inactivated Vaccine Sales Forecast by Regions (2021-2026) (K MT) Table 125. Global Inactivated Vaccine Sales Market Share Forecast by Regions (2021-2026) Table 126. Global Inactivated Vaccine Revenue Forecast by Regions (2021-2026) (US$ Million) Table 127. Global Inactivated Vaccine Revenue Market Share Forecast by Regions (2021-2026) Table 128. North America: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT) Table 129. North America: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million) Table 130. Europe: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT) Table 131. Europe: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million) Table 132. Asia Pacific: Inactivated Vaccine Sales Forecast by Region (2021-2026) (K MT) Table 133. Asia Pacific: Inactivated Vaccine Revenue Forecast by Region (2021-2026) (US$ Million) Table 134. Latin America: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT) Table 135. Latin America: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million) Table 136. Middle East and Africa: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT) Table 137. Middle East and Africa: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million) Table 138. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 139. Key Challenges Table 140. Market Risks Table 141. Main Points Interviewed from Key Inactivated Vaccine Players Table 142. Inactivated Vaccine Customers List Table 143. Inactivated Vaccine Distributors List Table 144. Research Programs/Design for This Report Table 145. Key Data Information from Secondary Sources Table 146. Key Data Information from Primary Sources List of Figures Figure 1. Inactivated Vaccine Product Picture Figure 2. Global Inactivated Vaccine Sales Market Share by Type in 2020 & 2026 Figure 3. Children Product Picture Figure 4. Adult Product Picture Figure 5. Global Inactivated Vaccine Sales Market Share by Application in 2020 & 2026 Figure 6. Hospital Figure 7. Medical Center Figure 8. Inactivated Vaccine Report Years Considered Figure 9. Global Inactivated Vaccine Market Size 2015-2026 (US$ Million) Figure 10. Global Inactivated Vaccine Sales 2015-2026 (K MT) Figure 11. Global Inactivated Vaccine Market Size Market Share by Region: 2020 Versus 2026 Figure 12. Global Inactivated Vaccine Sales Market Share by Region (2015-2020) Figure 13. Global Inactivated Vaccine Sales Market Share by Region in 2019 Figure 14. Global Inactivated Vaccine Revenue Market Share by Region (2015-2020) Figure 15. Global Inactivated Vaccine Revenue Market Share by Region in 2019 Figure 16. Global Inactivated Vaccine Sales Share by Manufacturer in 2019 Figure 17. The Top 10 and 5 Players Market Share by Inactivated Vaccine Revenue in 2019 Figure 18. Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 19. Global Inactivated Vaccine Sales Market Share by Type (2015-2020) Figure 20. Global Inactivated Vaccine Sales Market Share by Type in 2019 Figure 21. Global Inactivated Vaccine Revenue Market Share by Type (2015-2020) Figure 22. Global Inactivated Vaccine Revenue Market Share by Type in 2019 Figure 23. Global Inactivated Vaccine Market Share by Price Range (2015-2020) Figure 24. Global Inactivated Vaccine Sales Market Share by Application (2015-2020) Figure 25. Global Inactivated Vaccine Sales Market Share by Application in 2019 Figure 26. Global Inactivated Vaccine Revenue Market Share by Application (2015-2020) Figure 27. Global Inactivated Vaccine Revenue Market Share by Application in 2019 Figure 28. North America Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT) Figure 29. North America Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million) Figure 30. North America Inactivated Vaccine Sales Market Share by Country in 2019 Figure 31. North America Inactivated Vaccine Revenue Market Share by Country in 2019 Figure 32. U.S. Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 33. U.S. Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 34. Canada Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 35. Canada Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 36. North America Inactivated Vaccine Market Share by Type in 2019 Figure 37. North America Inactivated Vaccine Market Share by Application in 2019 Figure 38. Europe Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT) Figure 39. Europe Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million) Figure 40. Europe Inactivated Vaccine Sales Market Share by Country in 2019 Figure 41. Europe Inactivated Vaccine Revenue Market Share by Country in 2019 Figure 42. Germany Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 43. Germany Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 44. France Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 45. France Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 46. U.K. Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 47. U.K. Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 48. Italy Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 49. Italy Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 50. Russia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 51. Russia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 52. Europe Inactivated Vaccine Market Share by Type in 2019 Figure 53. Europe Inactivated Vaccine Market Share by Application in 2019 Figure 54. Asia Pacific Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT) Figure 55. Asia Pacific Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million) Figure 56. Asia Pacific Inactivated Vaccine Sales Market Share by Region in 2019 Figure 57. Asia Pacific Inactivated Vaccine Revenue Market Share by Region in 2019 Figure 58. China Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 59. China Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 60. Japan Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 61. Japan Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 62. South Korea Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 63. South Korea Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 64. India Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 65. India Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 66. Australia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 67. Australia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 68. Taiwan Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 69. Taiwan Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 70. Indonesia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 71. Indonesia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 72. Thailand Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 73. Thailand Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 74. Malaysia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 75. Malaysia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 76. Philippines Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 77. Philippines Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 78. Vietnam Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 79. Vietnam Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 80. Asia Pacific Inactivated Vaccine Market Share by Type in 2019 Figure 81. Asia Pacific Inactivated Vaccine Market Share by Application in 2019 Figure 82. Latin America Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT) Figure 83. Latin America Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million) Figure 84. Latin America Inactivated Vaccine Sales Market Share by Country in 2019 Figure 85. Latin America Inactivated Vaccine Revenue Market Share by Country in 2019 Figure 86. Mexico Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 87. Mexico Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 88. Brazil Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 89. Brazil Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 90. Argentina Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 91. Argentina Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 92. Latin America Inactivated Vaccine Market Share by Type in 2019 Figure 93. Latin America Inactivated Vaccine Market Share by Application in 2019 Figure 94. Middle East and Africa Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT) Figure 95. Middle East and Africa Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million) Figure 96. Middle East and Africa Inactivated Vaccine Sales Market Share by Country in 2019 Figure 97. Middle East and Africa Inactivated Vaccine Revenue Market Share by Country in 2019 Figure 98. Turkey Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 99. Turkey Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 100. Saudi Arabia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 101. Saudi Arabia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 102. U.A.E Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT) Figure 103. U.A.E Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 104. Middle East and Africa Inactivated Vaccine Market Share by Type in 2019 Figure 105. Middle East and Africa Inactivated Vaccine Market Share by Application in 2019 Figure 106. Astellas Pharma (Japan) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 107. CSL Limited (Australia) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 108. Emergent BioSolutions (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 109. GlaxoSmithKline (U.K.) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 110. Johnson & Johnson (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 111. MedImmune (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 112. Merck & Co (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 113. Pfizer (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 114. Sanofi Pasteur (France) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 115. Serum Institute of India Pvt (India) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 116. North America Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT) Figure 117. North America Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 118. Europe Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT) Figure 119. Europe Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 120. Asia Pacific Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT) Figure 121. Asia Pacific Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 122. Latin America Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT) Figure 123. Latin America Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 124. Middle East and Africa Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT) Figure 125. Middle East and Africa Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 126. Porter's Five Forces Analysis Figure 127. Channels of Distribution Figure 128. Distributors Profiles Figure 129. Bottom-up and Top-down Approaches for This Report Figure 130. Data Triangulation Figure 131. Key Executives Interviewed

Get Free Sample

Related Reports

COVID-19 Impact on Global Inactivated Vaccine, Market Insights and Forecast to 2026

Global Cushing's Syndrome Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Cushing's syndrome involves symptoms such as high blood pressure, abdominal obesity, round red face, a fatty lump between the shoulders, weak muscles and bones, acne, fragile skin and others. Most ...
read more

COVID-19 Impact on Global Inactivated Vaccine, Market Insights and Forecast to 2026

Global Tyrosine Kinase Inhibitors Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Tyrosine kinase inhibitors are small molecules that bind to the receptor site of the kinase enzyme available at cell surface. Scope of the Report: The global tyrosine kinase inhibitors market is e ...
read more

COVID-19 Impact on Global Inactivated Vaccine, Market Insights and Forecast to 2026

Global 2D Chromatography Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

2D chromatography is a type of chromatographic technique in which the injected sample is separated by passing through two different separation stages. This is done by injecting the eluent from the fir ...
read more

COVID-19 Impact on Global Inactivated Vaccine, Market Insights and Forecast to 2026

Global Astringent Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Astringent are used as an adjunct or alternative to standard suturing techniques to control bleeding or for wound closure. Scope of the Report: In 2018, North America is expected to account for th ...
read more

COVID-19 Impact on Global Inactivated Vaccine, Market Insights and Forecast to 2026

Global Disintegrants Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Disintegrants are agents added to tablet (and some encapsulated) formulations to promote the breakup of the tablet (and capsule “slugs') into smaller fragments in an aqueous environment thereby ...
read more


Choose License Type

Single User - This is a single user license, allowing one specific user access to the product.

Multi User - This is a 1-5 user licence, allowing up to five users have access to the product.

Enterprise User - This is an enterprise license, allowing all employees within your organisation access to the product. The report will be emailed to you.


Cards For Payment

Why Choose us

  • Lowest Price Guarantee
  • We offer the lowest prices for the listed reports
  • Data Security
  • Your data is safe and secure
  • Vast Report Database
  • We have more than 2 Million reports in our database
  • Client Focused
  • Personalized updates and 24*7 support
  • Trusted Source and Quality
  • We only work with reputable partners providing high quality research and support
  • Market Segmentation
  • We provide alternative views of the market to help you identify where the real opportunities lie
  • Bulk Discounts
  • We offer great discounts on purchase of multiple reports

Testimonials

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed.
-VP of a Automotive division in Germany

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements
-Product Manager at US based Manufacturer

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process
-Marketing Manager at a pharma company in Belgium

How To Reach Us

Reach out to our most senior Sales Professional-
Jay Matthews

+1 513 549 5911 (U.S.),
    +44 203 318 2846 (U.K.)
sales@marketresearchvision.com
 

Our Clients






Market Research Vision

About Us


Market Research Vision is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports. Serving as a market research firm, we help our clients in finding: what’s next? We believe in finding creative and innovative solutions through customized and syndicated research reports.
Read More


Contact Us


 
sales@marketresearchvision.com


+1 513 549 5911 (U.S.)
+44 203 318 2846 (U.K.)